All News #Library
Rare Diseases
Renalys Pharma Reports Positive Phase 3 Sparsentan Results
26 Nov 2025 //
PR NEWSWIRE
Renalys Pharma Backs Alport Syndrome Registry Study
22 Oct 2025 //
PR NEWSWIRE
Renalys Pharma Secure Japan PMDA Deal For Sparsentan Ph3 for FSGS
17 Oct 2025 //
PR NEWSWIRE
Sparsentan Receives Orphan Drug Designation for IgA Nephropathy
03 Dec 2024 //
PR NEWSWIRE

Market Place
Sourcing Support